“acute-lymphoblastic-leukemia” Archives

in
Entry Author Date Location
Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs 09/27/19 Boston
Precision Bio’s IPO Raises $126M for Pipeline of Gene-Edited Drugs 03/27/19 Raleigh Durham
Precision Bio Preps IPO to Test “Off-the-Shelf” Cancer Cell Therapy 03/04/19 Raleigh Durham
Allogene’s IPO Raises $288M for Tests of “Off-the-Shelf” Cell Therapy 10/11/18 San Francisco
Shire is Selling Cancer Business for $2.4B to Focus on Rare Disease 04/16/18 Boston
Ex-Kite Execs Resurface with $300M and Control of Pfizer CAR-T Cells 04/03/18 San Francisco
Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy 01/23/18 National
Juno Dissects ROCKET Deaths, Will Aim Better CAR-T at Leukemia 11/10/17 Seattle
FDA Lifts Hold on Cellectis’s “Off the Shelf” CAR-T, With Caveats 11/07/17 New York
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy 09/19/17 National
Novartis: CAR-T Results In One Month, Or No Charge. Why One Month? 08/31/17 National
Unanimous Advice To FDA: Approve Landmark CAR-T Cancer Therapy 07/12/17 National
Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More 03/31/17 National
Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More 01/27/17 National
Takeda to Buy Ariad in $5.2B Move to Build Up Cancer Drug Portfolio 01/09/17 Boston
At Late-Night ASH Talk, Juno Execs Look Beyond Stalled “Rocket” Trial 12/06/16 Seattle
In Year of CAR-T Trouble, Can Bluebird, Penn Make Headway in Myeloma? 11/30/16 Boston
Two More Deaths In Trial Halt Juno’s Top CAR-T Treatment Again 11/23/16 Seattle
All In One Place: A New Immuno-Oncology Trial Resource 10/19/16 National
After Three Deaths, FDA Halts Juno’s Leading CAR-T Trial 07/07/16 Seattle
Sean Parker To Fund CRISPR Trial, And Other Gene Edit Milestones 06/20/16 National
Reality Check: Cancer Experts Discuss Hurdles Facing CAR-T Therapy 09/18/15 National
ASCO Roundup: Checkpoints, Pushback Against Prices, CAR-T & More 06/02/15 National
Ariad Searches For New Leader As Berger Steps Down, Ending Proxy Battle 04/29/15 Boston
Seven Takeaways From “What’s Hot in Boston Biotech” 04/10/15 Boston
FDA’s Hamburg Stepping Down With Biopharma Turnaround as Her Legacy 02/05/15 National
Juno Just Raised A Ton of Cash. Here Comes the Spending Part. 12/19/14 Seattle
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
Immunotherapy Confidence (And Audience) Abundant At ASH T-Cell Talk 12/08/14 National
With Souped-Up Rituxan, Unum Plots First Foray Into T-Cell Therapy 12/01/14 Boston
Page 1 of 2 next page »